Partial
Mostly Aligned
Patient Risk:
Low
Summary
Claims about GOCOVRI being an extended-release capsule and indicated for levodopa-induced dyskinesia in patients receiving levodopa-based therapy are supported. However, some indication wording is partially incomplete (exclusion of “with or without concomitant dopaminergic medications”), and non-label claims about co-pay assistance and insurance coverage cannot be verified against the provided FDA prescribing information excerpts.
Category Scores
Accurate Statements
Gocovri is an extended-release capsule.
Label: “Dosage form: extended-release capsules” and “GOCOVRI is available as extended-release capsules for oral administration.”
Gocovri is indicated for the treatment of dyskinesia in patients with Parkinson's disease who are on dopaminergic therapy.
Label: Indications include “For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.”
Gocovri is approved for the treatment of Parkinson's disease levodopa-induced dyskinesia.
Label: Indications include “For the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy…”
Unsupported Statements
Adamas Pharmaceuticals offers co-pay assistance programs designed to reduce out-of-pocket costs for eligible commercially insured patients who meet certain criteria.
No information about co-pay assistance programs, eligibility criteria, or out-of-pocket cost reduction is included in the provided FDA prescribing information excerpts.
Adamas Pharmaceuticals co-pay assistance programs typically have annual maximum benefits.
No information about annual maximum benefits is included in the provided FDA prescribing information excerpts.
Gocovri is covered by many insurance plans.
No information about insurance coverage prevalence is included in the provided FDA prescribing information excerpts.
Insurance coverage details for Gocovri can differ by plan, including formulary status and co-payment requirements.
No information about formulary status or co-payment requirements is included in the provided FDA prescribing information excerpts.
Some insurance plans may require prior authorization for Gocovri.
No information about prior authorization is included in the provided FDA prescribing information excerpts.
Contradictions
Important Omissions
For the dyskinesia indication, the label specifies “receiving levodopa-based therapy, with or without concomitant dopaminergic medications.” The AI claim restricts this to being “on dopaminergic therapy” and does not include the label’s “with or without concomitant dopaminergic medications” phrasing.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Low
No dosing, contraindication, warning, interaction, or monitoring-related safety claims were made by the AI response. The only potentially material label-alignment issue is partial incompleteness in indication wording. Non-label insurance/co-pay claims are not verifiable from the provided prescribing information excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Mostly Aligned
Primary Issue
Non-label insurance/co-pay assistance assertions are not supported by the provided FDA prescribing information excerpts and cannot be validated against the label.
Suggested Improvement
Limit claims to sections supported by the prescribing information (e.g., dosage form and FDA indications). If discussing insurance or co-pay assistance, avoid stating specifics not present in the provided FDA label excerpts or clearly separate them from FDA labeling.